Reporter brief
Senolytics associated with changes in bone resorption markers in elderly women over 20 weeks
What happened
This phase 2 RCT tested whether senolytic drugs reduce senescent cells and alter bone metabolism markers in elderly women over 20 weeks. The study was open-label and single-center. The abstract states the objective but does not report the findings, sample size, effect sizes, or specific outcomes achieved.
Why it matters
Assessment pending; this report does not establish a change in evidence.
What it does NOT prove
- Limitations have not been recorded; consult the primary source.
Study design and sample
Rct; Human.
Elderly women
- Design
- Rct
- Sample
- —
- Journal
- Not clearly reported; author named as Sundeep Khosla, M.D.
- Published
- Jul 22, 2024
Effect size
Not recorded.
Caveats
- Assessment: Superseded.
- Only the source material recorded on this evidence page was assessed.
Conflicts and funding
Not recorded.
Previous evidence
See the Senolytics timeline and recorded assessment for prior evidence.
Primary source
Cancel Death charts and briefs may be reproduced editorially with attribution to CancelDeath.com. This brief is generated from the primary recorded source facts and assessment. Its review status is shown below; verify quotations against the paper before publication.